Ovid Therapeutics

Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule for treating epilepsies. It also develops OV882, a short hairpin RNA gene therapy for the treatment of angelman syndrome; and OV815 for the treatment of kinesin-family of proteins associated neurological disorder. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, and Northwestern University, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.

We are dedicated to transforming the lives of our patients and their families by developing medicines that are targeted, safe, and effective. We are committed to innovation and creativity, and strive to make a difference in the lives of those living with rare neurological disorders.

Our vision is to be the trusted leader in developing medicines that transform the lives of people with rare neurological disorders.

Ovid has won numerous awards, including the International Business Awards Grand Stevie Award, the Golden Bridge Awards, the Red Herring Top 100 North America award, and the Industrial Innovation Award from the National Organization for Rare Disorders .